These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 11489482)

  • 1. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
    Maeda H; Sawa T; Konno T
    J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent advances in research on SMANCS].
    Maeda H
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
    Fang J; Sawa T; Maeda H
    Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy.
    Maeda H
    Adv Drug Deliv Rev; 2001 Mar; 46(1-3):169-85. PubMed ID: 11259839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [SMANCS/lipiodol].
    Maeda H
    Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracavitary administration: pharmacokinetic advantages of macromolecular anticancer agents against peritoneal and pleural carcinomatoses.
    Kimura M; Konno T; Miyamoto Y; Kojima Y; Maeda H
    Anticancer Res; 1998; 18(4A):2547-50. PubMed ID: 9703908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Arterial infusion chemotherapy with SMANCS].
    Nekohashi T; Maruno J; Sanjou A; Toda G
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():629-33. PubMed ID: 11762025
    [No Abstract]   [Full Text] [Related]  

  • 8. SMANCS.
    Duncan R
    Jpn J Cancer Res; 1995 Jun; 86(6):inside front cover. PubMed ID: 7622412
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor-targeted chemotherapy with SMANCS in lipiodol for renal cell carcinoma: longer survival with larger size tumors.
    Tsuchiya K; Uchida T; Kobayashi M; Maeda H; Konno T; Yamanaka H
    Urology; 2000 Apr; 55(4):495-500. PubMed ID: 10736490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation.
    Oka K; Miyamoto Y; Matsumura Y; Tanaka S; Oda T; Suzuki F; Maeda H
    Pharm Res; 1990 Aug; 7(8):852-5. PubMed ID: 2146602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Styrene maleic acid neocarzinostatin treatment for hepatocellular carcinoma.
    Abe S; Otsuki M
    Curr Med Chem Anticancer Agents; 2002 Nov; 2(6):715-26. PubMed ID: 12678722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeted chemotherapy of hepatocellular carcinoma with SMANCS/Lipiodol--how to use SMANCS/Lipiodol].
    Konno T; Tabaru K; Isogai M; Nagamitsu A; Oda T
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():10-8. PubMed ID: 9512681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
    Nagamitsu A; Greish K; Maeda H
    Jpn J Clin Oncol; 2009 Nov; 39(11):756-66. PubMed ID: 19596662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of renal cell carcinoma with intra-arterial administration of SMANCS dissolved in Lipiodol.
    Noda S; Konno S; Tanaka J; Yamada M; Yoshitake N
    Anticancer Res; 1990; 10(3):709-15. PubMed ID: 2164351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
    Maeda H; Konno T
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):773-82. PubMed ID: 2985005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Arterial infusion chemotherapy with SMANCS-Lipiodol for multiple hepatocellular carcinoma].
    Takizawa K; Honda M; Obuchi M; Matsuoka S; Shima H; Uchiyama K; Hasebe S; Doai K; Satoh S; Kuniyasu Y
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():24-9. PubMed ID: 9512683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arterial infusion of SMANCS-Lipiodol for advanced hepatocellular carcinoma].
    Miura K; Nakao N; Yoshimoto A; Yamano T; Inoue J; Takayasu Y
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():51-5. PubMed ID: 9512688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Styrene maleic acid neocarzinostatin-transcatheter embolization for hepatocellular carcinoma--third report].
    Hasegawa I; Hirashima N
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):253-9. PubMed ID: 11865632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium].
    Maeda H
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of arterial infusion of SMANCS-dissolved Lipiodol in therapeutic strategies for hepatocellular carcinoma].
    Jin-no K
    Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():90-8. PubMed ID: 9512695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.